ArticleCancer research2008
Modulation of protective T cell immunity by complement inhibitor expression on tumor cells.
Article in Cancer research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Article
- Exploring program-cell death patterns to predict prognosis and sensitivity of cervical cancer immunotherapy via multi-omics analysis and clinical samples.Discover oncology · 2025Article
- The complement regulatory protein CD46 serves as a novel biomarker for cervical cancer diagnosis and prognosis evaluation.Frontiers in immunology · 2024Article
- Properdin Is a Modulator of Tumour Immunity in a Syngeneic Mouse Melanoma Model.Medicina (Kaunas, Lithuania) · 2021Article
- CD46 and Oncologic Interactions: Friendly Fire against Cancer.Antibodies (Basel, Switzerland) · 2020Review
- Complement System: a Neglected Pathway in Immunotherapy.Clinical reviews in allergy & immunology · 2020Review
- Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer.Frontiers in immunology · 2019Review
- The dual role of complement in cancer and its implication in anti-tumor therapy.Annals of translational medicine · 2016Review
- Radiotherapy: killing with complement.Annals of translational medicine · 2016Article
- Complement factor H polymorphism rs1061170 and the effect of cigarette smoking on the risk of lung cancer.Contemporary oncology (Poznan, Poland) · 2015Article
- Complement in monoclonal antibody therapy of cancer.Immunologic research · 2014Review
- Complement anaphylatoxins as immune regulators in cancer.Cancer medicine · 2014Review
- Distinct in vivo CD8 and CD4 T cell responses against normal and malignant tissues.Cancer immunology, immunotherapy : CII · 2013Article
- Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis.EMBO molecular medicine · 2012Article
- Article
- Article
- [The systemic evaluation and clinical significance of immunological function for advanced lung cancer patients].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2010Article
- Comparative proteomical and metalloproteomical analyses of human plasma from patients with laryngeal cancer.Cancer immunology, immunotherapy : CII · 2010Article
- Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack.Cancer immunology, immunotherapy : CII · 2009Article
- Is complement good or bad for cancer patients? A new perspective on an old dilemma.Trends in immunology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Complement-inhibitory proteins expressed on cancer cells can provide protection from antitumor antibodies and may potentially modulate the induction of an immune response to tumor-associated antigens. In the current study, we investigated the consequences of complement inhibitor down-regulation on the effector and inductive phases of an immune response. Stable small interfering RNA-mediated down-regulation of the complement inhibitor Crry on MB49 murine bladder cancer cells increased their susceptibility to monoclonal antibody and complement in vitro. In a syngeneic model of metastatic cancer, the down-regulation of Crry on i.v.-injected MB49 cells was associated with a significant decrease in tumor burden and an increase in the survival of challenged mice. However, monoclonal antibody therapy had no additional benefit. There was an antitumor IgG response, but the response was not effected by Crry down-regulation on inoculated tumor cells. Down-regulation of Crry on MB49 cells resulted in an enhanced antitumor T-cell response in challenged mice (measured by lymphocyte IFN-gamma secretion), and CD8+ T cell depletion of mice prior to injection of MB49 cells completely abrogated the effect of Crry down-regulation on tumor burden and survival. Deficiency of C3 also abrogated the effect of Crry down-regulation on the survival of MB49-challenged mice, indicating a complement-dependent mechanism. These data indicate that complement inhibitors expressed on a tumor cell can suppress a T cell response and that enhancing complement activation on a tumor cell surface can promote protective T cell immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.